Rolf M. Zinkernagel
Fondateur chez Hookipa Biotech AG
Profil
Rolf M.
Zinkernagel is the founder of Telormedix SA (2007), Hookipa Biotech AG (2011), and HOOKIPA Pharma, Inc. (2011).
He held former positions at Novartis AG as an Independent Non-Executive Director (2010-2014), Cytos Biotechnology AG as a Director (2003), the University of Zurich as a Professor & Director (2008), Novartis Institute for Functional Genomics, Inc. as a Director, Aravis AG as a Venture & Scientific Partner, and International Union of Immunological Societies as a Vice President.
Dr. Zinkernagel received his doctorate degree from the University of Basel in 1970.
Postes actifs de Rolf M. Zinkernagel
| Sociétés | Poste | Début |
|---|---|---|
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Fondateur | 01/07/2011 |
Anciens postes connus de Rolf M. Zinkernagel
| Sociétés | Poste | Fin |
|---|---|---|
| NOVARTIS AG | Directeur/Membre du Conseil | 25/02/2014 |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Private Equity Investor | 31/12/2013 |
| International Union of Immunological Societies | Corporate Officer/Principal | - |
| University of Zurich | Directeur/Membre du Conseil | 01/01/2008 |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Directeur/Membre du Conseil | 01/04/2003 |
Formation de Rolf M. Zinkernagel
| University of Basel | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NOVARTIS AG | Health Technology |
| HOOKIPA PHARMA INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
Aravis AG
Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Finance |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
Telormedix SA
 Telormedix SA Pharmaceuticals: MajorHealth Technology Telormedix SA operates as a biopharmaceutical company, that focuses on targeted immunity in the treatment of cancer and other diseases. Its products include TMX-101 for the treatment of localized bladder cancer, TMX-201 for the topical treatment of bladder cancer, skin cancer, and other indications, as well as for use as a vaccine adjuvant, and TMX-302 for use in preclinical trials for the treatment of autoimmune disease. The company was founded in October 2007 by Lorenzo Leoni, Roberto Maj, Rolf M. Zinkernagel and Dennis A. Carson and is headquartered in Lugano, Switzerland. | Health Technology |
| International Union of Immunological Societies | |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Health Technology |
